Enquirer Consulting Group

Reachable Buyer Map

Prepared for Amy Xue · CARBOGEN AMCIS · United States · August 2026
In development and manufacturing services, first contact usually happens at a congress, through a partner already inside a program, or at the point where a sponsor has decided to shop. That is a channel with a ceiling built into it: it reaches whoever is already circulating. This map is the rest, counted in the United States only, because that is where the sponsor buying sits rather than where the plant does. The sponsor and manufacturer segments a small molecule partner can reach by name, who signs inside each one, and roughly how many companies sit there.
Early phase sponsors
The point at which a molecule needs someone else's chemistry. A first outsourcing decision made here tends to carry through the later phases, so the segment is worth reaching before a program has a partner rather than after.
Who signs: head or VP of CMC, VP of technical operations, head of process chemistry. At emerging companies, the chief scientific officer or the CEO.
1,250 to 1,350
companies acting as industry lead sponsor on an active early phase drug trial with at least one US site
Late phase and registrational sponsors
Validation batches, process transfer and second source qualification. Slower to move and harder to displace, and the work is materially larger when it does land.
Who signs: VP of external manufacturing, head of supply chain, head of technical operations, regulatory CMC lead.
500 to 550
industry lead sponsors on an active phase 3 trial with a US site; many also sit in the band above, so the two bands are not additive
Conjugate and payload developers
Small by count and unusually specific by requirement. Containment, linker and payload chemistry narrow the field of possible partners before commercial terms are ever discussed, which is why this segment concentrates around whoever can prove the handling.
Who signs: VP of CMC, head of bioconjugation or technical operations, head of analytical development.
70 to 90
industry sponsors whose active US trial records describe an antibody drug conjugate
Commercial stage drug companies
Approved products already selling, so the conversation is second sourcing, capacity relief, cost of goods and lifecycle work rather than first time development. A longer qualification and a much longer tail once it is through.
Who signs: head of external manufacturing, VP of supply chain, direct materials procurement lead, site or technical head.
2,450 to 2,600
companies holding at least one registered US human drug establishment, animal feed operations excluded
Asset light and virtual developers
Companies that own the molecule and none of the plant. They appear as trial sponsors and never as registered establishments, so a list built from manufacturing registers misses them completely. This is the group most likely to need a full development partner rather than one step of it, and the hardest group to count.
Who signs: CEO or founder, chief scientific officer, and the head of CMC where that seat exists at all.
Not separately counted anywhere public
visible only where a company sponsors a trial and holds no registered site; no register enumerates the group directly

Where the openings are

1
The sponsor layer is finite, and every member of it is named in public. Roughly 1,550 to 1,650 companies currently act as industry lead sponsor on an active drug trial with a US site. The trial phase bands above are subsets of that number rather than additions to it. A market that can be listed by name is exactly where reaching every account beats waiting for the ones who circulate.
2
The buyer is a seat, not a company. Head of CMC, VP of external manufacturing, head of technical operations. Those seats turn over often in emerging companies, and a new holder almost always reopens the approved supplier list. A channel built on named roles catches that moment. A congress calendar catches whoever happened to attend.
3
US onshore capacity is a short list, so the comparison is technical rather than open. Fewer than 400 US firms carry an active API manufacture registration, across roughly 530 registered sites. When a sponsor works through where a molecule can actually be made, it is choosing between a small number of named options, and that choice is made in a conversation rather than a tender.
4
The asset light segment is the one bought lists cannot see. Anyone building from manufacturing registers reaches companies that own plants and misses companies that deliberately own none. Working that segment takes identification rather than purchase, which is why it stays open longer than the rest.
Built from public federal registry data: the current US drug establishment registration file and the public trial register, both read in August 2026. Counts are banded deliberately. Sponsor figures describe companies with at least one US trial site, so programs run entirely outside the United States are not in them, and a registration proves enumeration rather than capacity or quality. It describes the market rather than your business, and there is nothing to buy at the end of it.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com